Hainan Hailing Chemipharma Corp. Ltd.

Primary Objective: This study used merogalaline besylate tablets (licensed by Hainan Hailing Chemical Pharmaceutical Co., Ltd.) as the test formulation and merogalaline besylate tablets (Tarlige) (licensed by Daiichi Sankyo Co., Ltd.) as the reference formulation to conduct a human bioequivalence study under fasting and postprandial conditions to evaluate the bioequivalence of the test and reference formulations in healthy subjects. Secondary Objective: To observe the safety of the test and reference formulations in healthy participants.

Primary objective: To evaluate the bioequivalence of the two preparations in Chinese healthy subjects in the fasting and postprandial states, using Luqubopa Tablets (trade name: Wenkeda, specification: 3 mg) from Shionogi lnc. as the reference preparation and Luqubopa Tablets (specification: 3 mg) developed by Hainan Hailing Chemical Pharmaceutical Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in Chinese healthy subjects.

Primary objective: To evaluate the bioequivalence of the two preparations in healthy Chinese subjects in the fasting and fed state, using baricitinib tablets (trade name: Olumiant®, specification: 4 mg) from Eli Lilly Nederland B.V. as the reference preparation and baricitinib tablets (specification: 4 mg (in terms of C16H17N7O2S)) developed by Hainan Hailing Chemical Pharmaceutical Co., Ltd. as the test preparation. Secondary objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.